What is Karius?
Founded in 2014 and headquartered in Redwood City, California, Karius is at the forefront of providing genomic insights for infectious diseases. The company's innovative platform empowers clinicians to make more informed and timely treatment decisions, directly impacting patient outcomes. By leveraging advanced genomic analysis, Karius aims to revolutionize the diagnosis and management of infections, offering a crucial tool in the fight against disease.
How much funding has Karius raised?
Karius has raised a total of $320M across 4 funding rounds:
Other Financing Round
$5M
Series A
$50M
Unspecified
$165M
Series C
$100M
Other Financing Round (2014): $5M with participation from Innovation Endeavors, Data Collective, and Lightspeed Venture Partners
Series A (2017): $50M led by Tencent, Lightspeed Venture Partners, Pacific 8 Ventures, Data Collective, and Innovation Endeavors
Unspecified (2020): $165M supported by LightSpeed Venture Partners, HBM Healthcare Investments, SoftBank Vision Fund 21, General Catalyst, and Khosla Ventures
Series C (2024): $100M featuring HBM Healthcare Investments, Khosla Ventures, 5AM Ventures, General Catalyst, Seventure Partners, and Gilde Healthcare
Key Investors in Karius
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages. The firm deploys capital strategically to back entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
What's next for Karius?
With the infusion of this major strategic investment, Karius is poised for accelerated growth and further development of its diagnostic capabilities. The company is likely to expand its market reach, enhance its technological infrastructure, and potentially broaden its portfolio of infectious disease targets. This capital infusion signals a strong commitment from investors to support Karius's mission to transform infectious disease diagnostics and solidify its position as a leader in the field.
See full Karius company page
